Gefitinib induced convulsions: a rare case report


  • Atul J. Rajpara Department of Pharmacology, Medical College, Baroda, Gujarat, India
  • Neeta J. Kanani Department of Pharmacology, Medical College, Baroda, Gujarat, India



Drug induced convulsions, Gefitinib, Rare adverse drug reaction


Gefitinib, an epidermal growth factor receptor (EGFR) inhibitor is used as first-line therapy for non-small cell lung cancer and sometimes also used to treat the other metastatic carcinomas. Diarrhoea and pustular/papular rash occur in ~50% of patients taking gefitinib. Other side effects include dry skin, nausea, vomiting, pruritus, anorexia, and fatigue, but central side effects, especially convulsions are very rare. Here, we report a rare case of 60 years old female patient, a known case of carcinoma uterus with local metastasis and on high dose gefitinib (500 mg/day) treatment for 3 months, who developed generalized tonic-clonic seizure with frothing in mouth and postictal confusion. The dose of suspected medication was reduced to 250 mg/day and patient was given standard care for this adverse drug reaction.


Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther. 1999;82:241-50.

Chabner BA. Targeted therapies: tyrosine kinase inhibitors, monoclonal antibodies, and cytokines. In: Brunton LB, Lazo JS, Parker KL, eds. Goodman and Gilman's the Pharmacological Basis of Therapeutics. 12th ed. New York NY:McGraw-Hill; 2012:1539-1559.

VigiAccess™. Available at Accessed 8 August 2016.

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45.

Giaccone G, González-Larriba JL, van Oosterom AT. Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors. Ann Oncol. 2004;15:831-8.




How to Cite

Rajpara, A. J., & Kanani, N. J. (2016). Gefitinib induced convulsions: a rare case report. International Journal of Basic & Clinical Pharmacology, 5(6), 2692–2693.